[Practice and challenge of precision medicine for pancreatic cancer].

Pancreatic cancer is the most lethal malignancy with an overall 5-year survival rate less than 9%, mainly due to late diagnosis and lack of effective therapeutic options.In the last decade, post-operative survival has been enhanced with advent of neoadjuvant therapy and combined adjuvant therapy.Furthermore, the information gained from the omics data, including next generation sequencing data, hasn't yet begun to affect treatment of pancreatic cancer patients.However, in terms of precision medicine, pancreatic cancer has always lagged behind other tumors.Therefore, combined with practical experience, summary of the latest development and research progress of precise medical treatment of pancreatic cancer, especially from the fields of molecular biology and experimental models, is of critical importance. Further development of precise medicine for pancreatic cancer based on platforms using PDX and organoid model would promisingly help in effective improvement of clinical treatment.胰腺癌作为世纪顽症，一直受到广泛的关注与研究。近十年来，随着医疗体系的健全及治疗经验的累积，受益于联合化疗及新辅助治疗的研究进展，胰腺癌患者的预后得到了一定程度的改善。但在精准医疗方面，胰腺癌却始终缓步不前，远远滞后于其他肿瘤。因此，结合在胰腺癌精准医疗方面的实际探索经验与体会，综合国内外的最新研究进展，从分子生物学、实验模型等领域，深度认识目前胰腺癌在精准医疗方面的最新进展十分必要。尤其是基于人源肿瘤异种移植模型和类器官模型建立个体化精准治疗平台，将有望切实改善胰腺癌的研究与治疗手段，提高胰腺癌的治疗效果。.